Gram Negative Bacteremia, Risk Factors for Failure of Therapy

This study is currently recruiting participants.
Verified August 2012 by University of Pittsburgh
Sponsor:
Collaborator:
PI discretionary funding
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177957
First received: September 13, 2005
Last updated: August 23, 2012
Last verified: August 2012

September 13, 2005
August 23, 2012
April 2005
 
 
 
Complete list of historical versions of study NCT00177957 on ClinicalTrials.gov Archive Site
 
 
 
 
 
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
Gram Negative Bacteremia, Risk Factors for Failure of Therapy

The aims of this study are to:

  • Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli
  • Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli
  • Determine the risk factors for failure of prompt clearance of the blood of Gram negative bacteria
  • Determine the survival of patients with Gram negative bacteremia
  • Determine if failure of prompt clearance of the blood of Gram negative bacteria is a predictor of mortality following this infection

The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage within 14 days of onset of bacteremia, microbiological data and resistance patterns, choice of antibiotics once organism identified, suspected source of bacteremia, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history (please see attached clinical data collection worksheet dated 4/2005). We will also collect information retrospectively for one year and prospectively for one year. The bacteria in the patient's blood cultures will be subcultured (after the diagnosis has been obtained since the microbiology lab would otherwise destroy the culture) and provided to the honest broker who will deidentify the specimen and link it to the medical information collected (which will also be deidentified by the honest broker). The following evaluation will be performed on these samples. The minimal inhibitory concentration of the antibiotic used in treatment will be performed by the E-Test method (AB Biodisk, Solna, Sweden). Specific mechanisms of antimicrobial resistance will be studied with emphasis on the presence of beta-lactamases produced by the bacteria. This evaluation will be performed by analytical isoelectric focusing techniques as well as PCR and gene sequencing analysis to determine genes encoding beta-lactamases. Biologic samples will be under the control of the principal investigator of this research project. All samples provided to the investigators are deidentified by the honest broker and will be coded with numbers. The information linking these code numbers to the corresponding subjects' identities will be kept in a separate, secure location that only the honest broker has access to. The investigators on this study will keep the samples indefinitely. Samples will be kept in the investigator's laboratory located in Scaife Hall, room 812, 3500 Terrace Street. At no time with the research investigators have access to any patient identifiers.

Observational
Time Perspective: Prospective
 
Non-Probability Sample

patients with gram negative bacteremia

Gram-Negative Bacterial Infections
 
 
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
December 2015
 

Inclusion Criteria:

  • All patients at the aforementioned institutions that have Gram negative bacteremia will be included in the study.
  • Women with childbearing potential will also be included in this study. Since this is an observational study, no added risk is conferred to the woman or potential progeny. HIV serostatus will not be specifically investigated for participation in this study.

Exclusion Criteria:

  • None
Both
18 Years and older
No
Contact: Yohei Doi, MD 412-648-9445 yod4@pitt.edu
Contact: Diana Pakstis, RN, BSN 412-648-6553 dlp5@pitt.edu
United States
 
NCT00177957
IRB # 0504090
Yes
University of Pittsburgh
University of Pittsburgh
PI discretionary funding
Principal Investigator: Yohei Doi, MD University of Pittsburgh
University of Pittsburgh
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP